News | Embolization devices | February 24, 2016

ArtVentive Medical Group Inc. Announces Enrollment in OCCLUDE Post-Market Study

Researchers will examine ArtVentive EOS embolization device for venous and arterial cases

Artventive EOS embolization device, OCCLUDE post-market surveillance study, enrollment

Image courtesy of ArtVentive Medical Group Inc.

February 24, 2016 — ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE post-market surveillance study.

The study is dedicated to further advancement of use of the ArtVentive EOS embolization device in treating venous and arterial cases where the precise placement and immediate, efficient vessel embolization are paramount.

The first study case was performed at The University Hospital, Leuven, Belgium, where Geert Maleux, M.D., successfully treated a patient with the ArtVentive EOS device. Maleux, professor in the Department of Radiology stated, "The ArtVentive EOS device enhances our ability to treat challenging embolization cases. It offers immediate and complete occlusion. The operator can have confidence that the target vessel is occluded. The ArtVentive EOS technology allows for shorter procedure times and potentially reduced radiation exposure for both the physician and patient."

The device is catheter-based, self-expandable, and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body's vascular system and organ network.

For more information: www.artventivemedical.com

Related Content

Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
Overlay Init